%0 Journal Article
%T Fecal microbiota transplantation: great potential with many challenges
%A Richard Kellermayer
%J Archive of "Translational Gastroenterology and Hepatology".
%D 2019
%R 10.21037/tgh.2019.05.10
%X In January of 2019, Samuel P. Costello and colleagues published a wonderfully executed, double blind placebo-controlled trial on fecal microbiota transplantation (FMT) versus autologous stool as placebo in mild to moderately active adult ulcerative colitis [UC: one type of inflammatory bowel disease (IBD)] patients. This review-commentary examines the current state of knowledge on human gut microbiome (live microbiota + their products and surrounding environment, i.e., fecal matter) and microbial therapeutics from a gastrointestinal (GI) clinician¡¯s standpoint. The varied forms of dysbiosis as the target of FMT, recipient donor and placebo considerations are also discussed in respect to randomized control trials in IBD [and the lack thereof in Crohn¡¯s disease (CD)] with this unconventional treatment modality
%K Fecal microbiota transplantation (FMT)
%K ulcerative colitis (UC)
%K Crohn¡¯s disease (CD)
%K microbiome
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6556677/